12 Days of Regulatory Insights: Day 2 – How AGs Are Shaping Health Care Markets — Regulatory Oversight Podcast
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 250: Tariffs, Drug Pricing & Domestic Manufacturing with Gil Roth of PBOA
HHS Policy Changes, Supreme Court Rulings, and the DOJ-HHS False Claims Act Working Group
Taking the Pulse: A Health Care & Life Sciences Video Podcast | Episode 239: Understanding the 340B Pricing Program with Chuck Melendi of Disruptive Dialogue
Podcast — Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 220: Healthcare Regulation Under the Trump Administration with Bob Coble of Maynard Nexsen
Podcast — Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?
Podcast — Drug Pricing: What’s in the New CMS Medicaid Final Rule?
12 Days of Regulatory Insights: Day 3 - State AG Oversight in the Health Care Industry — Regulatory Oversight Podcast
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 216: Patient Advocacy and Healthcare Policy Change with Melissa Horn of the Arthritis Foundation
Podcast — Drug Pricing: Takeaways From the Chicago Medicaid Drug Rebate Program Summit
Podcast — Drug Pricing: How the Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry
Understanding Pharmacy Benefit Managers: The PBM Landscape Explained
Podcast — Drug Pricing: How Are Payers Responding to the IRA?
340B Drug Pricing Program Compliance
Inflation Reduction Act’s Drug Price Negotiation Provisions – What Now? – Diagnosing Health Care Podcast
Podcast: Inflation Reduction Act’s Drug Price Negotiation Provisions – What’s Next? - Diagnosing Health Care
Podcast: Chevron Deference: Is It Time for Change? - Diagnosing Health Care
On the Ballot 2020: Health Care Policy Outlook - Diagnosing Health Care Podcast
Podcast: IP(DC): Drug Prices, Political Pressures & Patents
Find the week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to provide you with a quick summary...more
On February 4, 2026, Express Scripts agreed to a settlement with the Federal Trade Commission (FTC) in the agency’s administrative case against the nation’s three largest pharmacy benefit managers (PBMs). Under the terms of...more
On Jan. 15, 2026, President Trump announced his “Great Healthcare Plan.” The plan focuses on four priority areas: lowering drug prices, lowering insurance premiums, holding big insurers accountable and maximizing price...more
The FTC reached a settlement with Express Scripts, Inc. and its affiliates (collectively “Express Scripts”) to resolve an administrative lawsuit alleging the pharmacy benefit manager violated Section 5 of the FTC Act by...more
As 2025 drew to a close, the Centers for Medicare & Medicaid Services (“CMS”) issued proposed rules for two mandatory pricing models aiming to reduce out-of-pocket costs for Medicare drugs....more
President Trump’s April 15, 2025, Executive Order on lowering the cost of prescription drug pricing, among other things, directed the Department of Labor (DOL) to propose regulations to improve the transparency of fees and...more
In our January 14 blog, we explained that Chief Judge Lance Walker of the U.S. District Court for the District of Maine had entered a nationwide preliminary injunction in American Hospital Association v. Kennedy, blocking the...more
GLP-1 medications, originally developed for diabetes and now widely used for weight management, are rapidly becoming a major cost concern for employer health plans. Annual costs per user often exceed $10,000, and demand is...more
U.S. Congress will largely return to normal operations this week, following passage of an appropriations package on February 3, 2026, that will fund the vast majority of federal agency operations through the end of 2026. ...more
The life sciences investment climate is looking up, as industry adapts to challenging supply-side forces and AI makes inroads in healthcare....more
On Feb. 3, 2026, President Donald Trump signed into law the Consolidated Appropriations Act, 2026 (CAA 2026), a sweeping piece of legislation including provisions that will substantially impact employer-sponsored health...more
The federal government recently delivered back-to-back measures forcing pharmacy benefit managers (PBMs) to be more transparent about their business models. However, with this heightened transparency comes a host of new...more
The ML Strategies 2026 Policy Outlook examines the major federal policy drivers expected to shape the business environment in 2026. The report covers congressional and executive branch priorities across six sectors including...more
On February 4, 2026, the Federal Trade Commission (FTC) announced a settlement and consent order in a long-running administrative action against pharmacy benefit managers (PBMs) Express Scripts, OptumRx, and Caremark Rx. The...more
Last week, the OIG posted two important issuances on Direct to Consumer drug programs, including TrumpRx – a Special Advisory Bulletin and a Request for Information (RFI)....more
This week, congressional attention will be mainly on funding for the US Department of Homeland Security (DHS) for fiscal year (FY) 2026, which is set to expire this Friday....more
On February 4, 2026, the Federal Trade Commission (FTC) announced what it called a “landmark” settlement with Express Scripts, Inc. (ESI) in its enforcement action alleging anticompetitive practices under Section 5 of the FTC...more
Here are curated AG and federal regulatory news stories highlighting key areas in which state and federal regulators’ decisions are having an impact across the US: •AG Campbell Cancels Crypto Kiosk Crooks - •AG Coalition...more
Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....more
Congress passed a package that funds the US Department of Health and Human Services through fiscal year 2026 and includes health extenders and additional bipartisan health policies....more
On February 3, 2026, Congress passed – and the President signed – the Consolidated Appropriations Act, 2026 (2026 CAA). The legislation includes a long‑anticipated and far‑reaching package of PBM reforms. These reforms draw...more
After a year defined by aggressive and often unorthodox executive action, the life sciences sector enters 2026 on the defensive. The Trump administration has shown little inclination to de-escalate, and the pressures of a...more
Health care policy will be at the center of Washington’s agenda in 2026. The midterm elections this November are already shaping the federal landscape and influencing Congress’s priorities. Affordability remains a top voter...more
Pursuant to the Inflation Reduction Act (the “IRA”), the Secretary of Health and Human Services (“HHS”) and the Center for Medicare & Medicaid Services (“CMS”) have begun the annual process of negotiating with pharmaceutical...more